omacetaxine

D. Anderson Cancer Center in Houston, the study evaluated the safety and efficacy of a potential new therapy called omacetaxine in patients with CML who have the T315I mutation and are resistant to first-line imatinib therapy.

The Earth Times Online Newspaper 2009

In the other study providing welcome news for CML patients, researchers reported that an older drug called omacetaxine stopped the cancer in many of these high-risk patients.

Latest Science News Features, Blog Entries, Column Entries, Issues, Articles and Book Reviews 2009

Omapro, or omacetaxine mepesuccinate, is secondary treatment aimed at those with chronic myeloid leukemia who do not improve with Novartis AG's Gleevec.

FinanzNachrichten.de: Aktuelle Nachrichten 2010

ChemGenex plans to commercialize omacetaxine itself in

The Earth Times Online Newspaper 2010

Omapro, or omacetaxine mepesuccinate, is secondary treatment aimed at those with chronic myeloid leukemia who do not improve with Novartis AG's Gleevec.

FinanzNachrichten.de: Aktuelle Nachrichten 2010

Chemgenex completes NDA submission for its omacetaxine mepesuccinate to the FDA

THE MEDICAL NEWS Editors 2010

ChemGenex Pharmaceuticals Limited (ASX: CXS) announced that positive safety findings from a combined analysis of two clinical trials for its lead product candidate, OMAPRO ™ (omacetaxine mepesuccinate), were presented today during a poster discussion session at the 2010 American

The Earth Times Online Newspaper 2010

The primary toxicity of omacetaxine is hematologic, with infrequent grade 3/4 non-hematologic events experienced;

The Earth Times Online Newspaper 2010

Injection site reactions were primarily grade 1/2 events, demonstrating that at-home subcutaneous administration of omacetaxine has an acceptable safety profile for CML patients who have failed prior therapies.

The Earth Times Online Newspaper 2010

ChemGenex has established a corporate alliance with Hospira to develop and commercialize omacetaxine in

The Earth Times Online Newspaper 2010